Head to Head Analysis: Quantum Biopharma (QNTM) & Its Rivals

Volatility and Risk

Quantum Biopharma has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500. Comparatively, Quantum Biopharma’s rivals have a beta of 3.67, meaning that their average share price is 267% more volatile than the S&P 500.

Valuation and Earnings

This table compares Quantum Biopharma and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Quantum Biopharma	N/A	-$17.90 million	-0.40
Quantum Biopharma Competitors	$1.83 billion	$139.20 million	-7.60

Quantum Biopharma’s rivals have higher revenue and earnings than Quantum Biopharma. Quantum Biopharma is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

1.2% of Quantum Biopharma shares are held by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 8.5% of Quantum Biopharma shares are held by company insiders. Comparatively, 13.6% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Quantum Biopharma and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Quantum Biopharma	N/A	-84.21%	-62.63%
Quantum Biopharma Competitors	-3,409.82%	-236.05%	-32.89%

Summary

Quantum Biopharma rivals beat Quantum Biopharma on 6 of the 9 factors compared.

Quantum Biopharma Company Profile

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.